Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma.

AIM To analyze the phenotype and function of dendritic cells (DC) from patients with hepatocellular carcinoma (HCC) in order to understand their role in this disease. METHODS Myeloid dendritic cells were enumerated in peripheral blood of HCC patients. CD80, CD83, CD86 and HLA-DR expression on naive and stimulated myeloid dendritic cells from peripheral blood were analyzed. Myeloid dendritic cells were isolated from peripheral blood and their function was tested. Phagocytosis was analyzed using FITC-dextran beads, peptide specific stimulation, the capacity to stimulate allogeneic T cells and secretion of cytokines upon poly dI:dC was tested. RESULTS Myeloid dendritic cells were reduced in patients with HCC. No differences in CD80, CD83, CD86 and HLA-DR expression were found on naive and stimulated myeloid dendritic cells from HCC patients and healthy controls. Normal phagocytosis or stimulation of peptide specific T cells was observed in contrast to an impaired allo-stimulatory capacity and a reduced IL-12 secretion. CONCLUSION Impaired IL-12 production of mDCs in patients could lead to an impaired stimulatory capacity of naive T cells suggesting that IL-12 directed therapies may enhance tumor specific immune responses in HCC patients.

[1]  J. Bruix,et al.  Treatment of hepatocellular carcinoma. , 2006, Critical reviews in oncology/hematology.

[2]  T. Greten,et al.  Therapie des hepatozellulären Karzinoms , 2006 .

[3]  M. Manns,et al.  Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients , 2005, British Journal of Cancer.

[4]  M. Manns,et al.  Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. , 2005, Cancer research.

[5]  Manal M. Hassan,et al.  Thalidomide in the treatment of patients with hepatocellular carcinoma , 2005, Cancer.

[6]  D. Speiser,et al.  Naturally Acquired MAGE-A10- and SSX-2-Specific CD8+ T Cell Responses in Patients with Hepatocellular Carcinoma1 , 2005, The Journal of Immunology.

[7]  D. Gabrilovich.  Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.

[8]  G. Gerken,et al.  Increased Levels of Interleukin-10 in Serum from Patients with Hepatocellular Carcinoma Correlate with Profound Numerical Deficiencies and Immature Phenotype of Circulating Dendritic Cell Subsets , 2004, Clinical Cancer Research.

[9]  L. Butterfield.  Immunotherapeutic strategies for hepatocellular carcinoma. , 2004, Gastroenterology.

[10]  A. Iwasaki,et al.  Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.

[11]  J. Kwekkeboom,et al.  Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B , 2004, Hepatology.

[12]  H. Rosen,et al.  Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease , 2004, Hepatology.

[13]  M. Manns,et al.  Spontaneous Tumor-Specific Humoral and Cellular Immune Responses to NY-ESO-1 in Hepatocellular Carcinoma , 2004, Clinical Cancer Research.

[14]  Wen‐Hsiung Chang,et al.  Salvage therapy for hepatocellular carcinoma with thalidomide. , 2004, World journal of gastroenterology.

[15]  C. Rice,et al.  Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. , 2004, Blood.

[16]  Josep Fuster,et al.  The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[17]  A. Riva,et al.  Altered maturation of peripheral blood dendritic cells in patients with breast cancer , 2003, British Journal of Cancer.

[18]  R. Foà,et al.  The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. , 2003, Cancer research.

[19]  M. Manns,et al.  Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. , 2002, Journal of immunological methods.

[20]  D. Olive,et al.  Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide , 2002, Journal of leukocyte biology.

[21]  C. Arias,et al.  Origin and differentiation of dendritic cells. , 2001, Trends in immunology.

[22]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[23]  A. Ribas,et al.  T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human α Fetoprotein1 , 2001, The Journal of Immunology.

[24]  F. Zoulim,et al.  Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. , 2001, Gastroenterology.

[25]  S. Miltenyi,et al.  BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood , 2000, The Journal of Immunology.

[26]  Yasuo Ohashi,et al.  Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial , 2000, The Lancet.

[27]  D. Carbone,et al.  Clinical significance of defective dendritic cell differentiation in cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  Bernardino,et al.  Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma , 2000, Hepatology.

[29]  S. Dubinett,et al.  Tumors Promote Altered Maturation and Early Apoptosis of Monocyte-Derived Dendritic Cells1 , 2000, The Journal of Immunology.

[30]  D. Davies,et al.  Human peripheral blood contains two distinct lineages of dendritic cells , 1999, European journal of immunology.

[31]  N. Horiike,et al.  Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. , 1999, Journal of hepatology.

[32]  S. Gangemi,et al.  Interleukin-12 and interleukin-10 production by mononuclear phagocytic cells from breast cancer patients. , 1999, Immunology letters.

[33]  N. Hayashi,et al.  Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. , 1999, Journal of immunology.

[34]  G. Duthie,et al.  Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[36]  M. Kojiro,et al.  Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration , 1998, Hepatology.

[37]  Jonathan M. Austyn,et al.  Dendritic cells , 1998, Current opinion in hematology.

[38]  E. Jaffee,et al.  Cancer Vaccines , 1997, Current protocols in human genetics.

[39]  J. Bruix,et al.  Treatment of hepatocellular carcinoma , 1997, Critical reviews in oncology/hematology.

[40]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[41]  G. Schuler,et al.  High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10 [published erratum appears in J Exp Med 1996 Oct 1;184(4):following 1590] , 1996, The Journal of experimental medicine.

[42]  A. Lanzavecchia,et al.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation , 1996, The Journal of experimental medicine.

[43]  M. Colombo,et al.  Amount of interleukin 12 available at the tumor site is critical for tumor regression. , 1996, Cancer research.

[44]  C Danieli,et al.  Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products , 1995, The Journal of experimental medicine.

[45]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[46]  O. Box.  Functional impairment of myeloid and plasmacytoid dendritic cells of pat ients with chronic hepatitis B , 2005 .

[47]  A. Ribas,et al.  T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. , 2001, Journal of immunology.

[48]  Bellia Mario,et al.  Prospective validation of the CLIP score, a new prognostic system for cirrhotic patients with hepatocellular carcinoma (RE: Hepatology 2000, 32/3: 679-80) , 2000 .

[49]  D. Carbone,et al.  Erratum: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells (Nature Medicine 2, 1096-1103 (1996)) , 1996 .

[50]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.